Association between enrolment in a heart failure quality registry and subsequent mortality—a nationwide cohort study. (23rd February 2017)

• Record Type: Journal Article
• Authors: Lund, Lars H.; Carrero, Juan‐Jesus; Farahmand, Bahman; Henriksson, Karin M.; Jonsson, Åsa; Jernberg, Tomas; Dahlström, Ulf
• Is Part Of: European journal of heart failure. Volume 19:Number 9(2017)
• Page Start: 1107
• Page End: 1116
• Publication Date: 2017-02-23
• Subjects: Heart failure -- Registry -- Evidence‐based medicine -- Guidelines -- Epidemiology; Heart failure -- Periodicals; Heart Failure -- Periodicals; Insuffisance cardiaque -- Périodiques; Heart failure; Periodicals; 616.129005
• DOI: 10.1002/ejhf.762
• Languages: English
• ISSNs: 1388-9842

Abstract

Abstract: Aims: Heart failure (HF) quality registries report quality of care but it is unknown whether they improve outcomes. The aims were to assess predictors of enrolment in a HF registry, test the hypothesis that enrolment in a HF registry is associated with reduced mortality, and assess potential explanatory factors for this reduction in mortality, if present. Methods and results: We conducted a nationwide prospective cohort study of patients with new‐onset HF registered in the Swedish National Patient Registry (NPR, a mandatory registry of ICD‐code diagnoses) with or without concurrent registration in the Swedish Heart Failure Registry (SwedeHF, a voluntary quality reporting registry) 2006–2013. The association between demographics, co‐morbidities and medications, and enrolment in the SwedeHF, was assessed using multivariable logistic regression. The association between enrolment in the SwedeHF and all‐cause mortality was assessed using multivariable Cox regression, with adjustment for demographics, co‐morbidities and medications. A total of 231 437 patients were included, of which 21 888 (9.5%) were in the SwedeHF [age (mean ± standard deviation) 74 ± 13 years; 41% women; 68% inpatients] and 209 549 (90.5%) were not (age 78 ± 12 years, 50% women; 79% inpatients). Selected variables independently associated with enrolment in the SwedeHF were male sex, younger age, higher education, absent co‐morbidities and co‐morbidity‐related medications, and use of HF and cardiovascular medications. Over a median (interquartile range) follow‐up of 874 (247–1667) days, there were 13.0 vs. 20.8 deaths per 100 patient‐years ( P < 0.001). The hazard ratio (95% confidence interval) for death for the SwedeHF yes vs. no was 0.65 (0.63–0.66) crude, and increased to 0.80 (0.78–0.81) after adding demographics, to 0.82 (0.80–0.84) after adding co‐morbidities and co‐morbidity‐related medications, to 0.95 (0.93–0.97) after adding cardiovascular medications, and to 1.04 (1.02–1.07) after adding HF‐specific medications. Conclusion: Heart failure patients of male sex, younger age, and higher education were more likely to be enrolled in a HF quality registry. Enrolment was associated with reduced all‐cause mortality that was explained by demographic differences and better utilization of cardiovascular and HF medications.